U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07839936) titled 'A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease' on Sept. 18.
Brief Summary: The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Atherosclerosis
Cardiovascular Disease
Hypercholesterolemia
Intervention:
DRUG: VERVE-102
Administered IV
DRUG: Placebo
Administered IV
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Verve Therapeutics, Inc.
Published by HT Digital Cont...